← Back to headlines
UBS Initiates Coverage on Jasper Therapeutics (JSPR) at Neutral
UBS has begun its coverage of Jasper Therapeutics (JSPR) with a 'Neutral' rating, despite acknowledging progress in the company's drug Briquilimab.
29 Mar, 20:50 — 29 Mar, 20:50
Sources
Showing 1 of 1 sources
Related Stories
Peter Obi Donates ₦10m to Ehime General Hospital in Nigeria
6m ago
Experts Recommend 30-Minute Daily Walks from Age 35 for Health Benefits
18m ago
Elderly 'Strong Silvers' Team, Aged 73-86, Maintains Daily Workout Routine
38m ago
Eli Lilly Extends Partnership with Insilico Medicine for AI Drug Discovery
45m ago